501 related articles for article (PubMed ID: 22198308)
1. Breaking the loop: oxytocin as a potential treatment for drug addiction.
McGregor IS; Bowen MT
Horm Behav; 2012 Mar; 61(3):331-9. PubMed ID: 22198308
[TBL] [Abstract][Full Text] [Related]
2. From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?
McGregor IS; Callaghan PD; Hunt GE
Br J Pharmacol; 2008 May; 154(2):358-68. PubMed ID: 18475254
[TBL] [Abstract][Full Text] [Related]
3. The role of oxytocin in alcohol and drug abuse.
King CE; Gano A; Becker HC
Brain Res; 2020 Jun; 1736():146761. PubMed ID: 32142721
[TBL] [Abstract][Full Text] [Related]
4. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
Clemens KJ; McGregor IS; Hunt GE; Cornish JL
Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
[TBL] [Abstract][Full Text] [Related]
5. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").
Thompson MR; Callaghan PD; Hunt GE; Cornish JL; McGregor IS
Neuroscience; 2007 May; 146(2):509-14. PubMed ID: 17383105
[TBL] [Abstract][Full Text] [Related]
6. Role of oxytocin in the neuroadaptation to drugs of abuse.
Sarnyai Z; Kovács GL
Psychoneuroendocrinology; 1994; 19(1):85-117. PubMed ID: 9210215
[TBL] [Abstract][Full Text] [Related]
7. MDMA ("ecstasy") abuse as an example of dopamine neuroplasticity.
Schenk S
Neurosci Biobehav Rev; 2011 Apr; 35(5):1203-18. PubMed ID: 21184779
[TBL] [Abstract][Full Text] [Related]
8. Oxytocin, Tolerance, and the Dark Side of Addiction.
Pedersen CA
Int Rev Neurobiol; 2017; 136():239-274. PubMed ID: 29056153
[TBL] [Abstract][Full Text] [Related]
9. Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.
van Nieuwenhuijzen PS; Long LE; Hunt GE; Arnold JC; McGregor IS
Psychopharmacology (Berl); 2010 Dec; 212(4):663-74. PubMed ID: 20730418
[TBL] [Abstract][Full Text] [Related]
10. Toward understanding how early-life social experiences alter oxytocin- and vasopressin-regulated social behaviors.
Veenema AH
Horm Behav; 2012 Mar; 61(3):304-12. PubMed ID: 22197269
[TBL] [Abstract][Full Text] [Related]
11. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.
Dumont GJ; Sweep FC; van der Steen R; Hermsen R; Donders AR; Touw DJ; van Gerven JM; Buitelaar JK; Verkes RJ
Soc Neurosci; 2009; 4(4):359-66. PubMed ID: 19562632
[TBL] [Abstract][Full Text] [Related]
12. Why social attachment and oxytocin protect against addiction and stress: Insights from the dynamics between ventral and dorsal corticostriatal systems.
Tops M; Koole SL; IJzerman H; Buisman-Pijlman FT
Pharmacol Biochem Behav; 2014 Apr; 119():39-48. PubMed ID: 23916423
[TBL] [Abstract][Full Text] [Related]
13. Neural correlates of MDMA ("Ecstasy")-induced social interaction in rats.
Thompson MR; Hunt GE; McGregor IS
Soc Neurosci; 2009; 4(1):60-72. PubMed ID: 18633827
[TBL] [Abstract][Full Text] [Related]
14. Oxytocin for the treatment of drug and alcohol use disorders.
Lee MR; Weerts EM
Behav Pharmacol; 2016 Dec; 27(8):640-648. PubMed ID: 27603752
[TBL] [Abstract][Full Text] [Related]
15. Substituting a long-acting dopamine uptake inhibitor for cocaine prevents relapse to cocaine seeking.
Velázquez-Sánchez C; Ferragud A; Ramos-Miguel A; García-Sevilla JA; Canales JJ
Addict Biol; 2013 Jul; 18(4):633-43. PubMed ID: 22741574
[TBL] [Abstract][Full Text] [Related]
16. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
Gillet C; Polard E; Mauduit N; Allain H
Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
[TBL] [Abstract][Full Text] [Related]
17. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
Molero-Chamizo A
Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
[TBL] [Abstract][Full Text] [Related]
18. The Multidimensional Therapeutic Potential of Targeting the Brain Oxytocin System for the Treatment of Substance Use Disorders.
Bowen MT; Neumann ID
Curr Top Behav Neurosci; 2018; 35():269-287. PubMed ID: 28942596
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date.
Lee MR; Rohn MC; Tanda G; Leggio L
CNS Drugs; 2016 Feb; 30(2):109-23. PubMed ID: 26932552
[TBL] [Abstract][Full Text] [Related]
20. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
